Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)33.98
  • Today's Change0.06 / 0.18%
  • Shares traded5.01m
  • 1 Year change+104.33%
  • Beta0.7225
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

  • Revenue in USD (TTM)17.26bn
  • Net income in USD1.41bn
  • Incorporated1944
  • Employees31.17k
  • Location
    Teva Pharmaceutical Industries Ltd124 Dvora Hanevi'a St.TEL AVIV-YAFO 6944020IsraelISR
  • Phone+972 39148213
  • Fax+972 39234050
  • Websitehttps://www.tevapharm.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Incyte Corp5.14bn1.29bn20.12bn2.84k15.793.8814.583.916.406.4025.6126.040.82914.335.481,807,750.0020.7511.3427.8314.3893.2693.9225.0316.483.25--0.00670.0021.2214.033,844.96---20.67--
United Therapeutics Corp3.13bn1.27bn20.39bn1.31k17.933.0815.066.5226.4126.4164.94153.610.43232.219.782,397,242.0017.5713.6119.4814.8488.5990.7940.6537.816.07--0.000.0023.6314.7121.35--24.11--
Royalty Pharma plc2.38bn770.95m26.07bn100.0025.384.0329.1410.961.781.784.2111.220.1257--84.5223,781,930.007.006.729.039.10----55.6850.56--7.060.479550.525.062.30-10.259.26-4.9024.01
Biogen Inc9.89bn1.29bn28.84bn7.50k22.321.5813.912.928.818.8167.37124.450.34411.045.301,318,747.004.506.705.327.9375.6978.4913.0717.282.035.740.25620.002.22-5.96-20.79-20.22-19.60--
Teva Pharmaceutical Industries Ltd (ADR)17.26bn1.41bn39.62bn31.17k28.024.9416.472.301.211.2114.896.880.4312.645.10553,620.103.50-1.475.25-2.0852.7250.588.13-4.040.80024.540.6799--4.320.709186.03---2.82--
Alnylam Pharmaceuticals, Inc.3.71bn313.75m41.70bn2.50k140.0352.74112.8811.232.252.2527.825.960.80688.467.201,485,575.006.82-12.289.57-16.1481.6483.208.45-24.702.713.500.7737--65.1949.77212.79---3.56--
Zoetis Inc9.47bn2.67bn53.46bn14.50k21.03--16.905.656.026.0221.33--------652,896.60--16.21--19.6171.8770.6828.2327.03--20.95--30.592.287.247.5210.296.5120.11
Data as of Feb 13 2026. Currency figures normalised to Teva Pharmaceutical Industries Ltd's reporting currency: US Dollar USD

Institutional shareholders

29.79%Per cent of shares held by top holders
HolderShares% Held
Harel Mutual Funds Ltd.as of 31 Dec 202544.95m3.92%
Phoenix Investments House Ltd.as of 31 Dec 202541.09m3.58%
Menora Mivtachim Insurance Ltd.as of 31 Dec 202539.32m3.43%
Clal Pension & Provident Funds Ltd.as of 31 Dec 202537.40m3.26%
Migdal Insurance Co. Ltd. (Investment Portfolio)as of 31 Dec 202537.40m3.26%
BlackRock Fund Advisorsas of 31 Dec 202535.79m3.12%
Norges Bank Investment Managementas of 31 Dec 202535.18m3.07%
Lingotto Investment Management LLPas of 31 Dec 202528.42m2.48%
Rubric Capital Management LPas of 31 Dec 202521.36m1.86%
PointState Capital LPas of 30 Sep 202520.71m1.81%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.